Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)

被引:643
作者
Ahn, Dae-Gyun [1 ]
Shin, Hye-Jin [1 ]
Kim, Mi-Hwa [1 ,2 ]
Lee, Sunhee [1 ]
Kim, Hae-Soo [1 ]
Myoung, Jinjong [3 ,4 ]
Kim, Bum-Tae [1 ]
Kim, Seong-Jun [1 ]
机构
[1] Korea Res Inst Chem Technol, Ctr Convergent Res Emerging Virus Infect, Daejeon 34114, South Korea
[2] Korea Inst Toxicol, Bioenvironm Sci & Toxicol Div, Gyeongnam Branch Inst, Jinju 52834, South Korea
[3] Jeonbuk Natl Univ, Korea Zoonosis Res Inst, Jeollabuk Do 54896, South Korea
[4] Jeonbuk Natl Univ, Genet Engn Res Inst, Jeollabuk Do 54896, South Korea
关键词
2019-nCoV; COVID-19; SARS-CoV-2; coronavirus; outbreak; RESPIRATORY SYNDROME CORONAVIRUS; PROTECTIVE IMMUNITY; AMINOPEPTIDASE-N; SPIKE PROTEIN; IN-VITRO; FUNCTIONAL RECEPTOR; VIRUS-INFECTION; SARS-COV; CHLOROQUINE; INHIBITION;
D O I
10.4014/jmb.2003.03011
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 090105 [作物生产系统与生态工程];
摘要
Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19.
引用
收藏
页码:313 / 324
页数:12
相关论文
共 83 条
[1]
Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study [J].
Al-Tawfiq, Jaffar A. ;
Momattin, Hisham ;
Dib, Jean ;
Memish, Ziad A. .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 20 :42-46
[2]
The future of vaccines, immunisation concepts and practice [J].
André, FE .
VACCINE, 2001, 19 (17-19) :2206-2209
[3]
[Anonymous], 2019, WHO MIDDLE E RESP SY
[4]
[Anonymous], 2020, KCDC COVID 19 SITUAT
[5]
[Anonymous], 2020, SARS COV 2 SARS COV, DOI DOI 10.1101/2020.02.16.951723
[6]
Presumed Asymptomatic Carrier Transmission of COVID-19 [J].
Bai, Yan ;
Yao, Lingsheng ;
Wei, Tao ;
Tian, Fei ;
Jin, Dong-Yan ;
Chen, Lijuan ;
Wang, Meiyun .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (14) :1406-1407
[7]
Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein [J].
Bisht, H ;
Roberts, A ;
Vogel, L ;
Subbarao, K ;
Moss, B .
VIROLOGY, 2005, 334 (02) :160-165
[8]
Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
[9]
A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus [J].
Chen, Yixin ;
Chan, Kwok-Hung ;
Kang, Yahong ;
Chen, Honglin ;
Luk, Hayes K. H. ;
Poon, Rosana W. S. ;
Chan, Jasper F. W. ;
Yuen, Kwok-Yung ;
Xia, Ningshao ;
Lau, Susanna K. P. ;
Woo, Patrick C. Y. .
EMERGING MICROBES & INFECTIONS, 2015, 4 :1-5
[10]
CHOY M, 2016, P & T, V41, P415